The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Risk of incident melanoma among individuals with low-count monoclonal B-cell lymphocytosis (MBL).
 
Bryan Alexis Vallejo
No Relationships to Disclose
 
Ahmed Ansari
No Relationships to Disclose
 
Sameer Ashok Parikh
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Genentech (Inst); Janssen (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Merck (Inst); NovalGen (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Janssen (Inst); Merck (Inst); TG Therapeutics (Inst)
 
Sara J Achenbach
No Relationships to Disclose
 
Kari G. Rabe
No Relationships to Disclose
 
Aaron Norman
No Relationships to Disclose
 
Janet E. Olson
Research Funding - Exact Sciences
 
James Robert Cerhan
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene (Inst); Protagonist Therapeutics
Research Funding - Celgene (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genmab (Inst); NanoString Technologies (Inst)
(OPTIONAL) Uncompensated Relationships - Regeneron (Inst)
 
Neil E. Kay
Consulting or Advisory Role - Abbvie (Inst); Acerta Pharma/AstraZeneca (Inst); Agios (Inst); AstraZeneca (Inst); BeiGene; Bristol-Myers Squibb (Inst); Celgene (Inst); CSL Behring; CytomX Therapeutics (Inst); DAVA Pharmaceuticals (Inst); Genentech/Abbvie (Inst); Janssen Biotech (Inst); Juno Therapeutics (Inst); MEI Pharma (Inst); MorphoSys (Inst); Oncotracker (Inst); Pharmacyclics (Inst); Rigel (Inst); Sunesis Pharmaceuticals (Inst); Targeted Oncology (Inst); TG Therapeutics (Inst); Tolero Pharmaceuticals (Inst)
Research Funding - Abbvie; Acerta Pharma; Bristol-Myers Squibb; Celgene; Genentech; MEI Pharma; Pharmacyclics/Janssen; Sunesis Pharmaceuticals; TG Therapeutics; Tolero Pharmaceuticals
 
Celine M. Vachon
Stock and Other Ownership Interests - Exact Sciences (I)
Research Funding - GRAIL (Inst)
Patents, Royalties, Other Intellectual Property - Breast Density software
 
Esteban Braggio
No Relationships to Disclose
 
Curtis A Hanson
No Relationships to Disclose
 
Christian Baum
No Relationships to Disclose
 
Tait D. Shanafelt
Research Funding - Celgene (Inst); Cephalon (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hospira (Inst); Pharmacyclics (Inst); Polyphenon E International (Inst)
Patents, Royalties, Other Intellectual Property - Dr. Shanafelt is co-inventor of the Well-being Index Instruments (Physician Well-being Index; Nurse Well-being Index; Medical Student Well-being Index; Well-being Index) and the Mayo Clinic Participatory Management Leadership Index. Mayo Clinic holds the
 
Susan L. Slager
No Relationships to Disclose